Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial

Abstract

Nephrol Dial Transplant 2017 gfx043. doi: 10.1093/ndt/gfx043 In the published version of this article Table 1 contained errors in the first column. The corrected version of Table 1 is given below: Demographics characteristics at TEMPO 3:4 and TEMPO 4:4 baseline Data are given as means with standard deviation (SD), or as median with interquartile range (IQR) when appropriate. BL, baseline. The early-treatment group received tolvaptan in TEMPO 3:4 and the late-treatment group received placebo. The author apologises for this error, which has now been corrected.